CLH Healthcare

Cell and Gene Therapy

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

MedTech

BioAge Labs, Inc. | August 24, 2022

BioAge Labs, Inc. a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it has initiated a partnership agreement with Age Labs AS a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study biobank collected from more than 100,000...

MedTech, Industrial Impact

Atreca, Inc. | February 07, 2023

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...

Cell and Gene Therapy

Antengene | June 28, 2022

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1...